Drug Trial Radar · NCT07820085
A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
225
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Mar 2029
Study completion Sep 2029
Sponsor
- Lead sponsor
- Portal Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PATHWAY is a Phase 2b/3 clinical study with an Open-Label Extension (OLE). It tests PORT-77 in patients with EPP, EPP2, and XLP. The study has three parts: Part 1: Phase 2b * Find the right dose of PORT-77 to lower PPIX levels in the blood * Test if PORT-77 lowers PPIX levels better than placebo * Check the safety of each dose Part 2: Phase 3 * Test if PORT-77 lowers PPIX levels better than placebo * Test if PORT-77 increases the amount of time patients spend in sunlight each day without pain compared to placebo * Check the safety of PORT-77 Part 3: Open-Label Extension (OLE) * Test the long-term effect of PORT-77 on PPIX levels and time in sun * Monitor long-term safety
Conditions
- Erythropoietic Protoporphyria (EPP)
- X-Linked Protoporphyria (XLP)
- EPP2
Interventions
PORT-77Drug
Oral tablets
PlaceboDrug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma metal-free PPIX concentration changeTime frame: Part 1 - Days 1 through 84; Part 2 - through Day 182; Part 3 - through Month 12
- Adverse EventsTime frame: Part 1 - Day 1 through Day 84; Part 2 - through Day 182; Part 3 - through Month 12
- Average daily time in sunlight without painTime frame: Part 2 - Day 155 through 182
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Investigative Site
Huntington Beach, California · Recruiting
Investigative Site
Cincinnati, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.